Publications by authors named "Farhan Israr"
Article Synopsis
- Type 2 diabetes (T2DM) increases the risk of cardiovascular diseases, prompting a study comparing the cardiovascular benefits of two medications, dapagliflozin and empagliflozin, known as SGLT2 inhibitors.
- A comprehensive analysis of twelve studies found that while dapagliflozin was better at preventing atrial fibrillation compared to empagliflozin, no significant differences were noted in other cardiovascular outcomes like major adverse events and mortality.
- Both medications were effective at reducing cardiovascular risks in T2DM patients, but dapagliflozin's lower atrial fibrillation risk could influence treatment choices, especially for at-risk individuals.
Article Synopsis
- * Results showed that IVUS guidance significantly reduced the risk of major adverse cardiac events (MACE) and stent thrombosis compared to angiography guidance, while also favoring better outcomes in secondary measures like cardiac mortality and myocardial infarction.
- * Although IVUS showed advantages in reducing the need for repeat procedures, factors like cost-effectiveness and the requirement for specialized training must be addressed for its broader implementation in clinical settings.
